Table II.
Differential expression of PRDX family members in tumor types.a
| PRDX family member | Expression levels in different tumor types | Refs. |
|---|---|---|
| PRDX1 | Increased in: Lung cancer, bladder cancer, ovarian carcinoma, aggressive esophageal squamous carcinomas, mesothelioma, glioblastoma, hilar cholangiocarcinoma, esophageal squamous cell carcinoma, liver cancer and pancreatic cancer | (60–67,142) |
| Decreased in: Thyroid tumors (PTCs) | (74,75) | |
| PRDX2 | Increased in: Colorectal cancers, B cell-derived primary lymphoma cells, vaginal carcinoma, cervical cancer, ovarian cancer, prostate cancer, esophageal cancer and B-cell-derived primary lymphoma cells | (87–92,94) |
| Decreased in: Melanoma | (85) | |
| PRDX3 | Increased in: Hepatocellular carcinomas, malignant mesothelioma, breast carcinoma, prostate cancer, cervical carcinoma and lung cancer | (67,102–106) |
| PRDX4 | Increased in: Pancreatic cancer, prostate cancer, oral cavity squamous cell carcinoma, colorectal cancer, breast cancer, ovarian cancer and lung cancer | (70,90,114,116–119) |
| Decreased in: Pancreatic cancer and acute promyelocytic leukemia | (113,121) | |
| PRDX5 | Increased in: Aggressive Hodgkin lymphomas, malignant mesothelioma, breast carcinoma, ovarian carcinoma and thyroid cancer | (67,87,103,127,128) |
| Decreased in: Adrenocortical carcinoma | (129) | |
| PRDX6 | Increased in: Breast cancer, malignant mesothelioma, bladder cancer, esophageal cancer, lung cancer, ovarian cancer, pancreatic cancer, cancer of the gingivo-buccal area and lymphoma | (61,67,87,141–146) |
| Decreased in: Thyroid tumors | (75,149) |
a
A summary is provided of the different types of cancer in which the expression of individual members of the PRDX family is up or downregulated. PRDX, peroxiredoxin; PTCs, papillary thyroid carcinomas.